Diagnostic And Monitoring Microneedles: The Technology Race Between Silicon‑Based Bionic And Biolinq
May 12, 2026
In the field of medical diagnostic monitoring, microneedle technology is driving a disruptive transformation in the continuous glucose monitoring (CGM) market. Silicon‑Based Bionic and Biolinq represent groundbreaking technological breakthroughs from China and the United States, respectively.
Innovation by Silicon‑Based Bionic
Silicon‑Based Bionic's self‑developed Silicon‑Based Dynamic CGM System adopts second‑generation glucose‑sensor technology, enabling 24‑hour continuous and real‑time monitoring via implantable flexible microneedles. These hair‑thin microneedles penetrate the interstitial fluid layer of subcutaneous tissue with near‑painless insertion. Over a 14‑day wear period, patients are freed from routine finger‑prick blood sampling, substantially reducing repeated puncture pain and infection risk. The device achieves a measurement error below 8.7 %. With medical‑grade accuracy, calibration‑free pain‑free operation, and real‑time data tracking, it breaks the long‑term monopoly of global giants over core CGM technologies.
Technological Breakthrough by Biolinq
In September 2025, U.S.‑based Biolinq secured FDA approval for its microneedle‑electrode‑array‑based continuous glucose monitor, Biolinq Shine. Constructed from multiple independent microneedle electrodes, the design mitigates the time‑dependent signal drift common in conventional electrochemical sensors, delivering higher‑precision glucose readings. Its electrode array is 20 times smaller than competitor microneedles, delivering near‑non‑invasive performance and drastically reducing patient discomfort. Biolinq's glucose sensor avoids penetration into pain‑sensitive dermal nerve tissue, minimizing pain perception.
Technical Comparison
Traditional CGM sensors such as Abbott's FreeStyle Libre series and Dexcom's G‑Series rely on a single 5–6 mm needle‑shaped electrode inserted deep into the dermis to capture glucose signals from interstitial fluid. This design suffers from two critical drawbacks: first, patients' psychological aversion and physical pain caused by long‑needle insertion; second, single‑point failure risk - once the electrode is encapsulated by biofilm or suffers signal drift, the entire sensor becomes non‑functional. By contrast, microneedle‑array technology reduces electrode length to 1 mm, just one‑fifth to one‑tenth of conventional devices, greatly lowering pain and failure risk.
UK Startup Sava
In August 2025, UK health‑tech firm Sava closed a USD 19 million Series‑A round, bringing total funding to USD 32 million, targeting mass production of its microneedle‑electrode‑based continuous glucose monitor. Founded in 2019 by bioengineers Renato Circi and Rafael Michali from Imperial College London, Sava is developing a wearable biosensor capable of real‑time detection of multiple subcutaneous biomarkers.
Chinese Research Progress
A wearable microneedle patch developed by the Shenzhen Institutes of Advanced Technology enables ultrasound‑assisted non‑invasive continuous glucose monitoring. A standard ultrasound probe reads microneedle length variations, converting glucose levels into quantifiable acoustic signals. A joint team led by Associate Professor Yang Jian (University of South China), Professors Jiang Lelun and Yi Changqing (Sun Yat‑sen University), and Professor Hossam Haick (Technion‑Israel Institute of Technology) has developed a microneedle‑based Continuous Drug/Biomarker Monitoring (MCBM) system, designed for minimally invasive real‑time monitoring of glucose and metformin concentrations in the interstitial fluid of diabetic patients.
Market Outlook
Glucose monitoring is a highly lucrative business, generating billions of U.S. dollars in annual revenue for Abbott and Dexcom. In 2024, the two companies' combined CGM revenue exceeded USD 10 billion (Abbott: USD 6.8 billion; Dexcom: USD 4.023 billion). The adoption of microneedle technology is expected to disrupt this duopoly, offering patients more comfortable and cost‑effective monitoring solutions.
